Bio & Pharma
KOICA donates Celltrion's Herzuma to Ukraine
The Ukrainian government specifically requested a supply of the cancer-fighting drug Herzuma
By Dec 26, 2022 (Gmt+09:00)
1
Min read
Most Read
S.Korea's LS Materials set to boost earnings ahead of IPO process
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Galaxy Ring, new foldables set to steal the show at Samsung Unpacked Paris
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
POSCO gears up for carbon-free steelmaking with hydrogen
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
SK Inc. in talks to sell Pharmteco’s US CDMO plant to Novo Nordisk
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
South Korea sets sights on fostering EDA tech to win HBM chip war
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
![Herzuma, Celltrion's breast and gastric cancers treatment](https://www.kedglobal.com/data/ked/image/2022/12/26/ked202212260027.630x.0.jpg)
Celltrion Healthcare Co. said on Monday that Herzuma (ingredient name: Trastuzumab) was dispatched to patients in Ukraine by the Korea International Cooperation Agency (KOICA).
The latest donation was led by KOICA at the Ukrainian government's request. KOICA purchased 5 billion won ($3.9 million) worth of Herzuma from Celltrion Healthcare and donated it to Ukraine.
It is understood that the Ukrainian government selected Herzuma after considering the efficacy and safety of treatment, and the trust it has gained with European doctors, given that the supply of treatments for breast and stomach cancers was disrupted by the war.
Trastuzumab is one of the best-known anti-cancer drugs and has been widely used in Europe for years to treat HER2-positive breast cancer and gastric cancer.
"As we are currently running the Remsima SC donation program in Turkey and Pakistan, we will continue to fulfill our social responsibility to promote global medical welfare," said a Celltrion Healthcare official.
Write to Jung-Eun Kim at likesmile@hankyung.com
More to Read
-
-
Bio & PharmaCelltrion to seek FDA approval for sale of Remsima SC by year-end
Nov 28, 2022 (Gmt+09:00)
1 Min read -
Bio & PharmaCelltrion wins trial against Regeneron for US patent lawsuit over biosimilar
Nov 18, 2022 (Gmt+09:00)
1 Min read -
EarningsCelltrion's Q3 earnings boosted by Remsima sales in Europe
Nov 09, 2022 (Gmt+09:00)
1 Min read
Comment 0
LOG IN